The WST‐1 assay indicated that treatment of miR‐99a with an inhibitor significantly abrogated the effect of aripiprazole on the proliferation of CRC cells (Figure 5P), suggesting that the RNH1/miR‐99a/mTOR regulatory axis is involved in the anticancer bioactivity of aripiprazole. The gene discussed is MTOR; the disease is colorectal carcinoma.